Schizophrenie

T. Wobrock; F.-G. Pajonk; P. Falkai

doi:10.1055/s-2003-812472

Fortschritte der Neurologie · Psychiatrie, Table of Contents

Fortschr Neurol Psychiatr 2004; 72(3): 164-174
DOI: 10.1055/s-2003-812472

Fort- und Weiterbildung

Schizophrenie

Teil II: Verlauf, Diagnostik und DifferenzialdiagnostikSchizophreniaPart II: Course of Illnes, Diagnostics and Differential DiagnosisT. Wobrock¹ , F.-G. Pajonk¹ , P. Falkai¹

¹Universitäts-Nervenklinik - Psychiatrie und Psychotherapie - Universitätskliniken des Saarlandes, Homburg/Saar

Abstract

Full Text

References

Literatur(Gesamtverzeichnis Teil I und II)

1 Andreasen N C. Scale for the assessment of negative symptoms. Iowa City: University of Iowa 1983
2 Andreasen N C. Scale for the assessment of positive symptoms. Iowa City: University of Iowa 1983
3 Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie (AMDP) .Manual zur Dokumentation psychiatrischer Befunde. 7. unveränderte Auflage. Hogrefe 2000
4 Arolt V, Lancer R, Nolte A, Miller-Myhsok B, Purmann S, Schürmann M, Leutelt J, Pinno W M, Schwinger E. Eye tracking dysfunction as putative phenotypic susceptibility marker of schizophrenia and maps to a locus on chromosome 6p in families with multiple occurance of the disease. Am J Med Genet. 1996; 67 564-679
5 Asarnow R F, Nuechterlein K H, Subotnik K L, Fogelson D L, Torquato R D, Payne D L, Asamen J, Mintz J, Guthrie D. Neurocognitive impairments in nonpsychotic parents of children with schizophrenia and attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2002; 59 1053-1060
6 Bebbington P E, Bowen J, Hirsch S R, Kuipers E A. The clinical utility of expressed emotion in schizophrenia. Acta Psychiatr Scand. 1994; 89 (Suppl 382) 46-53
7 Besthehorn M, Tischer B, Glaser P, Mast O, Schmidt D. Repräsentative Studie zur Verteilung schizophrener Patienten auf medizinische Versorgungseinrichtungen in Deutschland. Fortschr Neurol Psychiat. 1999; 67 487-492
8 Blackwood D H, Whalley L J, Christie J E, Blackburn I M, St. Clair D M, McInnes A. Changes in auditory P3 event-related potential in schizophrenia and depression. Br J Psychiatry. 1987; 150 154-160
9 Carlsson A, Lindqvist M. Effect of chlorpromazine and haloperidol on formation of methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol. 1963; 20 140-144
10 Crow T J. The two syndrome concept: origins and current status. Schizophr Bull. 1985; 11 471-486
11 Davidson M, Reichenberg A, Rabinowitz J, Weiser M, Kaplan Z, Mark M. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am J Psychiatry. 1999; 156 1328-1335
12 Dilling H, Mombour W, Schmidt M H. Internationale Klassifikation psychischer Störungen. ICD-10 - Kapitel V (F). Klinisch-diagnostische Leitlinien. Bern, Göttingen, Toronto: Huber 1999
13 Egan M F, Goldberg T E, Kolachana B S, Callicott J H, Mazzanti C M, Straub R E, Goldman D, Weinberger D R. Effect of COMT Val 108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA. 2001; 98 6917-6922
14 Falkai P, Honer W G, Schneider-Axmann T. Entorhinal cortex pre-alpha-cell clusters in schizophrenia: quantitative evidence of a developmental abnormality. Biol Psychiatry. 2000; 47 937-943
15 Falkai P, Honer W G, Alfter D, Schneider-Axmann T, Bussfeld P, Cordes J, Blank B, Schönell H, Steinmetz H, Maier W, Tepest R. The temporal lobe in schizophrenia from uni- and multiply affected families. Neurosci Lett. 2002; 325 25-28
16 Freedman R, Coon H, Myles-Worsly M, Orr-Urtreger A, Olincy A, Davis A, Polymropoulus M, Holik J, Hopkins J, Hoff M, Rosenthal J, Waldo M C, Reimherr F, Wander P, Yaw J, Young D A, Presse C R, Adams C, Petterson D, Adler L E, Kruglyak L, Leonhard S, Byerley W. Linkage of a neurophysiological defizit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA. 1997; 94 587-592
17 Fuller R, Nopoulos P, Arndt S, O'Leary D, Ho B C, Andreasen N C. Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance. Am J Psychiatry. 2002; 159 1183-1189
18 Gallinat J, Riedel M, Juckel G, Sokullu S, Frodl T, Moukhtieva R, Mavrogiorgou P, Nisslé S, Müller N, Danker-Hopfe H, Hegerl U. P300 and symptom improvement in schizophrenia. Psychopharmacology. 2001; 158 55-65
19 Gottesmann E I, Bertelsen A. Confirming an expressed genotype for schizophrenia. Arch Gen Psychiatry. 1989; 46 867-872
20 Häfner H, Heiden W an der. Course and outcome of schizophrenia. In: Hirsch SR, Weinberger DR (eds). Schizophrenia. Massachusetts, Oxford, Victoria, Berlin: Blackwell Science 2003: 101-141
21 Hakak Y, Walker J R, Li C, Wong W H, Davis K L, Buxbaum J D, Haroutunian V, Fienberg A A. Genome-wide expression analysis reveals dysregulation of myelinisation-related genes in chronic schizophrenia. Proc Natl Acad Sci USA. 2001; 98 4746-4751
22 Harris E C, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry. 1998; 173 11-53
23 Harrison P J, Owen M J. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet. 2003; 361 417-419
24 Hegarty J D, Baldessarini R J, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: a meta-analysis of the outcome-literature. Am J Psychiatry. 1994; 151 1409-1416
25 Heinrichs R W, Zakzanis K K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998; 12 426-445
26 Hoff A L, Sakuma M, Wieneke M, Horon R, Kushner M, DeLisi L E. Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia. Am J Psychiatry. 1999; 156 1336-1341
27 Jablensky A. Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci. 2000; 250 274-285
28 Jones P B, Rantakallio P, Hartikainen A L, Isohanni M, Sipila P. Schizophrenia as a long-term outcome of pregnancy, delivery, and perinatal complications: a 28-year follow-up of the 1966 north Finland general population birth cohort. Am J Psychiatry. 1998; 155 355-364
29 Kay S R, Fiszbein A, Opler L A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13 261-277
30 Keshavan M S, Stanley J A, Pettegrew J W. Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings - part II. Biol Psychiatry. 2000; 48 369-380
31 Kissling W, Höffler J, Seemann U, Müller P, Rüther E, Trenckmann U, Uber A, Schulenburg J M Graf v. d., Glaser P, Glaser T, Mast O, Schmidt D. Die direkten und indirekten Kosten der Schizophrenie. Fortschr Neurol Psychiat. 1999; 67 29-36
32 Klosterkötter J, Schultze-Lutter F. Gibt es eine Primärprävention schizophrener Psychosen?. Fortschr Neurol Psychiat. 2001; 69 Sonderheft 2 S104-S112
33 Kovanaszay B, Bromet E, Schwarz J E, Ram R, Lavelle J, Brandon L. Substance use disorder and onset of psychotic illness. Hosp Community Psychiatry. 1993; 44 567-571
34 Laruelle M, Abi-Dargham A, Casanova M F, Toti R, Weinberger D R, Kleinman J E. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. Arch Gen Psychiatry. 1993; 50 810-818
35 Loebel A D, Lieberman J A, Alvir J M, Mayerhoff D I, Geisler S H, Szymanski S R. Duration of psychosis and outcome in first episode schizophrenia. Am J Psychiatry. 1992; 149 1183-1188
36 Maier W, Lichtermann D, Rietschel M, Held T, Falkai P, Wagner M, Schwab S. Genetik schizophrener Störungen. Neuere Konzepte und Befunde. Nervenarzt. 1999; 70 955-969
37 Meltzer H Y. Biological studies in schizophrenia. Schizophr Bull. 1987; 13 77-111
38 Nuechterlein K H, Dawson M E, Ventura J, Gitlin M, Subotnik K L, Snyder K S, Mintz J, Bartzokis G. The vulnerability/stress model of schizophrenic relapse. Acta Psychiatr Scand. 1994; 89 (Suppl. 382) 58-64
39 Overall J D, Gorham D R. The Brief Psychiatric Rating Scale. Psychol Rep. 1962; 10 799-812
40 Perlstein W M, Carter C S, Noll D C, Cohen J D. Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia. Am J Psychiatry. 2001; 158 1105-1113
41 Potkin S G, Alva G, Fleming K, Anand R, Keator D, Carreon D, Doo M, Jin Y, Wu J C, Fallon J H. A PET study of the pathophysiology of negative symptoms in schizophrenia. Am J Psychiatry. 2002; 159 227-237
42 Regier D A, Farmer M E, Rae D S, Locke B Z, Keith S J, Judd L L, Goodwin F K. Comorbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiologic Catchment Area (ECA) study. JAMA. 1990; 264 2511-2518
43 Schmitt A, Weber-Fahr W, Jatzko A, Tost T, Henn F A, Braus D F. Aktueller Überblick über strukturelle Magnetresonanztomographie bei Schizophrenie. Fortschr Neurol Psychiat. 2001; 69 105-115
44 Smith R C, Hussain M I, Chowdhury S A, Stearns A. Stability of neurological soft signs in chronically hospitalised schizophrenic patients. J Neuropsychiatry Clin Neurosci. 1999; 11 91-96
45 Vogeley K, Tepest R, Pfeiffer U, Schneider-Axmann T, Maier W, Honer W G, Falkai P. Right frontal hypergyria differentiates affected from non-affected siblings in families with schizophrenia. A morphometric MRI study. Am J Psychiatry. 2001; 158 494-496
46 Webster M J, Knable M B, O'Grady J, Orthmann J, Weickert C S. Regional specifity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Mol Psychiatry. 2002; 7 985-994

Dr. med. Thomas Wobrock

Universitäts-Nervenklinik · Psychiatrie und Psychotherapie · Universitätskliniken des Saarlandes

66421 Homburg/Saar

Email: thomas.wobrock@uniklinik-saarland.de